Certara has announced the launch of Hasharc, its decentralized application (DApp) for healthcare, built in conjunction with the Hedera public Distributed Ledger Technology (DLT). Hasharc has been built on Certara’s OpenPharma technology platform.
The need for increased traceability and security in the life science industry is rapidly increasing, as evidenced by regulations including FDA’s Drug Supply Chain Security Act and the EU’s General Data Protection Regulation (GDPR), along with several clinical trials transparency regulations. Certara’s OpenPharma is being leveraged to address these challenges, especially as they impact patient safety and privacy protections.
The release of Hasharc coincided with Hedera’s own milestone of Open Access for the mainnet network and the introduction of the mirrornet. Hasharc leverages both the mainnet and the mirrornet and builds on other key technological advances of the Hedera platform as well.
Certara has been a Hedera user and partner since its infancy. “We are proud of our association and collaboration with Hedera,” said Jim Nasr, VP of Technology and Innovation, and Head of Certara’s OpenPharma innovation unit.
"We're excited to see Certara be one of the very first implementations of a Hedera mirror node, to provide reporting and analytics for transactions on the Hedera network, particularly for healthcare and supply chain use cases," said Mance Harmon, Co-founder and CEO of Hedera. "We are committed to working alongside Certara on the pioneering work they're doing around OpenPharma and realizing the potential of distributed technology for the healthcare industry to deliver improved outcomes and lower cost for patients."
Last year, Certara leveraged Hedera DLT to develop the OpenPharma proof of concept for tracking the generic drug supply chain in the US. Since then, Certara has continued to evolve its OpenPharma platform to support additional blockchain-based use cases, including: Blockchain-on-FHIR (accessing patient data through HL7 FHIR APIs in real time), real-time data anonymization and lay summary secure collaborations.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.